- JP-listed companies
- SUSMED, Inc.
- Income statement
SUSMED, Inc. (4263) Income statement
Market cap
¥16.8B
P/E ratio
Susmed develops digital therapeutic apps and IT platforms that help pharmaceutical companies and healthcare providers conduct clinical trials and analyze medical data more efficiently.
| 2017/06 | 2018/06 | 2019/06 | 2020/06 | 2021/06 | 2022/06 | 2023/06 | 2024/06 | 2025/06 | |
| Revenue | - | 2 | 5 | 35 | 115 | 317 | 531 | 343 | 463 |
| Revenue growth (%) | - | - | |||||||
| Operating margin (%) | - | - | - | ||||||
| Operating expenses | - | - | - | 108 | 190 | 309 | 395 | 452 | 477 |
| Operating income | - | - | - | -161 | -333 | -229 | -48 | -365 | -299 |
| Income before tax | -12 | -129 | -215 | -89 | -271 | -217 | -44 | -357 | -295 |
| Pretax margin (%) | - | -7,716.7 | -4,280.8 | -254.6 | -234.7 | -68.6 | -8.4 | -104.3 | -63.6 |
| Provision for income taxes | - | - | - | 0 | 2 | 0 | 1 | 1 | 1 |
| Effective tax rate (%) | - | - | - | ||||||
| Net income | -12 | -133 | -217 | -97 | -278 | -233 | -51 | -357 | -298 |
| Net income margin (%) | - | ||||||||
| Earnings per share | -1,110.4 | -9,748.94 | -13,198.14 | -8.42 | -21.69 | -15.9 | -3.09 | -21.41 | -17.77 |
| Dividend per share | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | ||||||
| EBITDA margin (%) | - | - | - |